Overview: OncoPro Comprehensive Cancer Panel TestIntroduction: The OncoPro Comprehensive Cancer Panel Test screens 161 genes to diagnose various cancers, causing pain or weight loss. Aligned with 2023 ASCO guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected cancers, such as breast, lung, or colorectal cancer.
Other Names: Comprehensive Cancer Assay, 161-Gene Cancer Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Comprehensive cancer panels began in the 2010s with NGS advancements. Targeted gene panels improved diagnostic precision for multiple cancers.
Purpose: Screens 161 genes to diagnose various cancers, guides treatment, and evaluates patients with pain or weight loss.
Test Parameters: 1. 161 Cancer Genes
Pretest Condition: No fasting required. Collect whole blood or tissue. Report history of pain, weight loss, or cancer symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Tissue (sterile container, 0.5-2 cma³). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document pain, weight loss, lumps, or family history of cancer. Include current medications, especially chemotherapy or targeted therapies.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to screen 161 cancer-related genes (e.g., BRCA1, TP53). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for cancer diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm cancer, guiding targeted therapies or surgery. Negative results may require tissue biopsy.
Specialist Consultation: Consult an oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Tissue biopsy, imaging (CT/MRI), or tumor markers to confirm cancer diagnosis.
Test Limitations: Not all cancers have detectable mutations; clinical correlation is needed. Sample quality affects sensitivity.
References: ASCO Cancer Guidelines, 2023; Journal of Clinical Oncology, Chakravarty D, 2022.
